CPASS are providing support, advocacy and education to patients and healthcare professionals considering medicinal cannabis treatments within the patient care pathway.
CPASS work with and support patients as well as their medical teams and deliver CPD accredited courses.
Recent YouGov polls indicate that over 1.4 million patients in the UK are currently consuming cannabis to help manage their diagnosed medical conditions with a further 6.7 million adult patients who would like to discuss cannabis-based treatment options with their healthcare teams.
Changes to UK law in November 2018 allow specialist doctors to prescribe cannabis-based medicinal products (CBMPs) under certain circumstances.
Most CBMPs are unlicensed, meaning that they have not been through the full tests and evaluations, like other medicines provided by the NHS, and can only be prescribed in exceptional circumstances to patients where other licensed medicines have been tried or are unsuitable. Unlicensed medicines, such as cannabis, are classified as ‘specials’.
The use of CBMPs are only currently recommended by the National Institute of Health are Care Excellence (NICE) for chronic pain, spasticity in multiple sclerosis, chemotherapy-induced nausea and vomiting as well as severe and intractable epilepsy in children.
CPASS will support patients and their medical teams by providing educational resources and advocacy for those considering CBMPs.
CPASS also works to destigmatise the consumption of cannabis for medicinal purposes for the benefit of patients and their families who are currently consuming cannabis or are considering it.
We have never introduced a new medicine into our healthcare systems that thousands of patients have already been consuming as a medicine for many decades.
There is significant anecdotal evidence that cannabis can be highly efficacious for a wide range of conditions, namely due to the chemical compounds found within the plant which are called (Phyto) cannabinoids.
Cannabinoids are the main active ingredients in cannabis and more than 160 have been identified by scientists. They can be produced by the human body, found in plants and manufactured in a laboratory under clinical conditions for use in certain prescription medications.